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Abstract
Human Ntera2/cl.D1 (NT2) cells treated with retinoic acid (RA) differentiate towards a well characterized neuronal
phenotype sharing many features with human fetal neurons. In view of the emerging role of caspases in murine stem cell/
neural precursor differentiation, caspases activity was evaluated during RA differentiation. Caspase-2, -3 and -9 activity was
transiently and selectively increased in differentiating and non-apoptotic NT2-cells. SiRNA-mediated selective silencing of
either caspase-2 (si-Casp2) or -9 (si-Casp9) was implemented in order to dissect the role of distinct caspases. The RA-induced
expression of neuronal markers, i.e. neural cell adhesion molecule (NCAM), microtubule associated protein-2 (MAP2) and
tyrosine hydroxylase (TH) mRNAs and proteins, was decreased in si-Casp9, but markedly increased in si-Casp2 cells. During
RA-induced NT2 differentiation, the class III histone deacetylase Sirt1, a putative caspase substrate implicated in the
regulation of the proneural bHLH MASH1 gene expression, was cleaved to a ,100 kDa fragment. Sirt1 cleavage was
markedly reduced in si-Casp9 cells, even though caspase-3 was normally activated, but was not affected (still cleaved) in si-
Casp2 cells, despite a marked reduction of caspase-3 activity. The expression of MASH1 mRNA was higher and occurred
earlier in si-Casp2 cells, while was reduced at early time points during differentiation in si-Casp9 cells. Thus, caspase-2 and -9
may perform opposite functions during RA-induced NT2 neuronal differentiation. While caspase-9 activation is relevant for
proper neuronal differentiation, likely through the fine tuning of Sirt1 function, caspase-2 activation appears to hinder the
RA-induced neuronal differentiation of NT2 cells.
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Introduction
The human teratocarcinoma cell line Ntera2/cl.D1 (NT2 cells)
represents a well-established model to study the retinoic acid (RA)-
induced terminal differentiation of human neural progenitors into
post-mitotic neurons (NT2-N) [1–3]. The many features that
NT2-N share with human fetal neurons has generated great
interest for their potential use as graft source for cell therapy in
neurodegenerative diseases [4], a perspective that warrants a deep
understanding of the molecular mechanisms underlying NT2 cell
differentiation.
Caspases, cysteine-dependent aspartate-specific proteases, are
classified according to phylogenetic relationships, structure, sub-
strate specificity, location in signaling pathways (‘‘initiator’’, i.e.
upstream activator of the apoptotic cascade, or ‘‘executioner’’, i.e.
effector of apoptosis) and function. The functional definition of
‘‘apoptotic’’ and ‘‘pro-inflammatory’’ caspases defines the two
best-studied processes in which these proteases are operative,
though it may not include all their possible functions [5,6].
Apoptosis occurs massively in the developing brain, where it
eliminates neurons that fail to reach their proper targets and helps
shaping/refining neuronal networks. However, caspase’s implica-
tion in neurodevelopment may exceed the morphogenetic and
‘‘systems matching’’–i.e. modulation of optimal connectivity
between neurons and their targets or afferents– role fulfilled by
apoptosis in the developing brain [7]. Indeed, following the
seminal observation by Ishizaki et al. [8], the implication of
caspases in the differentiation of diverse cell types, and particularly
neurons, as well as in various aspects of neuronal plasticity, is
becoming more accepted [9–11]. Across species, both ‘‘initiator’’
and ‘‘executioner’’ caspases appear involved in neuronal differen-
tiation/maturation, and the evidence gathered thus far in the
mammalian brain appears to suggest the ultimate involvement of
caspase-3 [11–16]. Whether the latter is a necessary requirement
or an epiphenomenon consequent to the hierarchical activation of
caspases, as shown to occur following appropriate stimuli leading
to apoptosis [5], is so far unclear.
Sirt1 is a NAD
+-dependent class III histone/lysine deacetylase
whose activity is implicated in chromatin remodeling, transcrip-
tional silencing, stress response and cellular differentiation [17,18].
Sirt1 also appears to regulate in a redox-dependent manner
murine neural precursor differentiation, where conditions de-
termining its activation or inhibition direct neural precursors
towards the glial or the neuronal lineage, respectively, by
controlling the expression of the proneural bHLH factor MASH1
[19]. Of particular relevance in this context, is the finding that,
under apoptotic conditions, Sirt1 was shown to be cleaved by
caspases-1, -3,-6, -8 and -9 [20].
Neuronal differentiation is relevant not only to shape the brain
connectivity during development but also in the context of
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neuronal progenitors may represent an adaptive approach to
replace, at least in part, the neurons that are killed, though not
exclusively, by caspase activation [7,10]. Hence, as the available
evidence suggests [11–16], caspases may behave as double edge
swords in the pathophysiology of neurodegenerative diseases.
Following this line of thinking, caspase’s pharmacological in-
hibition, albeit beneficial in reducing/slowing down neuronal
death [21–24], theoretically may hinder the intrinsic brain
neurogenic potential. Altogether, these considerations prompted
us to evaluate whether and which caspases are operative in the
differentiation of NT2 cells.
The present results show that although the activity of caspase-2,
-3 and -9 is transiently increased during the RA-induced
differentiation of NT2 cells, caspase-2 and 9 appear to play the
most relevant, though opposite, roles in the process. In fact,
siRNA-mediated silencing of caspase-9 delays/reduces the expres-
sion of neuronal markers in differentiating non-apoptotic NT2
cells. The silencing of caspase-9 expression also greatly reduces the
cleavage of Sirt1 that occurs during NT2-cell differentiation.
Hence, caspase-9 activation seems relevant for the proper RA-
induced neuronal differentiation of NT2 cells, likely through the
fine-tuning of Sirt1 function. In contrast, silencing of caspase-2
increases the expression of neuronal differentiation markers,
suggesting that caspase-2 activation operates as a restraining
mechanism on NT2 cell differentiation.
Materials and Methods
Cell Culture
NT2 cells (ATCC, Manassas, VA, USA) were grown in DMEM
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal
bovine serum (FBS), 1% glutamine and penicillin/streptomycin
(10,000 UI/ml and 10 mg/ml, respectively) and were induced to
differentiate following a cell aggregation protocol [25], with minor
modifications [3]. Retinoic acid (1 mM) was added to the cultures
twice weekly for 4 weeks. Post-mitotic neurons were obtained by
replating the cells on Matrigel (BD, San Jose, CA, USA)-coated
dishes, in fresh medium containing mitotic inhibitors (1 mM
cytosine arabinoside, 10 mM fluorodeoxyuridine, 10 mM uridine)
to reduce proliferation of non-neuronal cells. After 10–15 days of
treatment with mitotic inhibitors the cultures contained .99%
pure post-mitotic neurons (NT2-N).
Removal of Apoptotic Cells
Non-apoptotic cells were purified from apoptotic ones by
negative selection using the Apoptotic cell isolation kit (Biovision,
CA, USA). Briefly, the cells were collected, washed twice with PBS
cells and re-suspended in binding buffer containing Annexin V-
biotin, according to the manufacturer’s instructions. After in-
cubation at room temperature for 15 min in the dark, the cells
were washed, re-suspended in binding buffer containing strepta-
vidin-coated magnet beads and incubated for 15 min at room
temperature. The apoptotic Annexin V-positive cells were
separated from living cells using a magnetic surface (Dynal
MCP-S, Invitrogen).
Caspase Activity Assay
Quantitative enzymatic activity assays were carried out as
previously described [26]. Fifty mg of total cell lysates were assayed
for caspase activity using 7-amino-4-trifluoromethylcumarin
(AFC)-conjugated peptide substrates: YVAD-AFC, VDVAD-
AFC, DEVD-AFC, VEID-AFC, IETD-AFC and LEHD-AFC
(Biovision, CA, USA) as specific for caspase-1, -2, -3, -5, -6, -8 and
-9, respectively. Briefly, cytosolic cell lysates were incubated with
each fluorogenic substrate in appropriate buffer for 2 h at 37uC.
The peptide-AFC was hydrolyzed by the enzyme and the
fluorescence measured using a Victor plate fluorometer (Perki-
nElmer, MA, USA) at Ex400/Em505 nm. Some assays were
performed in the presence of broad spectrum caspase inhibitor Z-
VAD-FMK (20 uM) (Biovision).
siRNA Constructs and Stable Transfection of NT2 Cells
Kits of Ready-cloned HuSH 29mer shRNA against human
caspase-2 and -9 in pGFP-V-RS plasmids were purchased from
Origene (Rockville, MA, USA). Each kit included four shRNA
constructs targeting different regions of each gene. NT2 cells were
separately transfected with each construct to identify the shRNA
that caused maximum inhibition for subsequent experiments. Cells
were transfected using Lipofectamine 2000 (Invitrogen), following
the manufacturer’s instructions. Forty-eight hours after trans-
fection, cells were selected by adding 1 mg/ml puromycin. Stably
transfected NT2 cells were maintained in medium containing
1 mg/ml puromycin. Silencing of caspase-2 or -9 gene was
confirmed by RT-PCR and Western blotting for each clone that
carried a stable transfection. The following shRNA sequences were
selected and used for experiments in which caspase-9 and-2 were
interfered, respectively: AGG ATT TGG TGA TGT CGA GCA
GAA AGACC and CAA GGC CAC CTG GAG GAT ATG
TTG CTC AC. Control NT2 cells also received a plasmid
containing a non-effective 29-mer scrambled shRNA in pGFP-V-
RS to take into account non-specific effects of the shRNA.
Real Time PCR
NT2 cells were harvested at the indicated time points. Taqman
quantitative real-time PCRs (NCAM, MAP2, TH, Mash1,
GAPDH) were performed using commercially available Assay-
On-Demand kits, n. Hs00941821_m1, Hs00258900_m1,
Hs00165941_m1, Hs00269932_m1 and 4333764F, respectively
(Applied Biosystems, Inc., Foster City, CA, USA). Total RNA was
isolated from NT2 using the RNeasy plus mini-kit (Qiagen,
Hilden, Germany) and the concentration was determined by
spectrophotometry. For the generation of the first strand cDNA,
1 mg of total RNA was reverse transcribed by random primer
extension using SuperScript III reverse transcriptase (Invitrogen)
according to the manufacturer’s instructions. Gene expression
assays were performed according to manufacturer’s instructions,
with an ABI 7300 cycler. Triplicate CT values were analyzed in
Microsoft Excel using the comparative CT(DDCT) method,
according to the manufacturer’s instructions. The amount of
target transcript (2
2DDCT) was obtained by normalizing the values
to endogenous GAPDH.
Antibodies and Western Blot Analysis
Antibodies: polyclonal anti-nCAM (R&D Systems, Minneapo-
lis, USA), polyclonal anti-TH (Millipore, Billerica, MA, USA),
polyclonal anti-caspase-9, monoclonal anti-caspase-2 and poly-
clonal anti-PARP (Cell Signal Technology, Danvers, USA),
polyclonal anti-Sirt1 and monoclonal anti-bactin (Sigma, St Louis,
USA), Goat anti-mouse and goat anti-rabbit HRP (GE Health-
care, Bio-Sciences Corp., NJ, USA) were used as secondary
antibodies. Western blotting: NT2 cells were collected, lysed in
RIPA buffer containing 25 mM Tris-HCl pH 7.6, 150 mM NaCl,
1% NP-40, 1% sodium deoxycholate, 0.1% SDS and protease
inhibitors (protease inhibitor cocktail, Sigma). Protein concentra-
tion for each sample was determined by Bio-Rad protein assay
reagent (Bio-Rad Laboratories, Inc, Richmond, CA, USA),
separated by SDS-PAGE and transferred to PVDF blotting
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for 2 hr at RT with 5% fat free dried milk and incubated
overnight with primary antibodies. After washing, the membranes
were incubated with HRP-conjugated secondary antibody for 1 h
at RT. The protein signals were visualized using the ECL-Plus
Chemiluminescence kit (GE Healthcare, USA). Densitometric
analysis was performed with TINA image software (version 2.09f,
Raytest, Straubenhardt, Germany).
Statistical Analysis
The data, representing the means 6 SD of three experiments,
each run either in duplicate or triplicate, were analyzed by
ANOVA followed by post-hoc Dunnett test or by Kruskal-Wallis
test, followed by post-hoc Student-Neuman-Keuls test, as appro-
priate.
Results
Caspase-2, -3 and -9 Activities Selectively Increase During
RA-induced Neuronal Differentiation of NT2 Cells
Among various caspases examined, only caspase-2, -3 and -9
were transiently but significantly activated during RA treatment
(RA, Figure 1 A, B and C). For each caspase assay, control samples
were run in parallel in the presence of the pan-caspase inhibitor z-
VAD-fmk (z-VAD-fmk, Figure 1 A-C). As the substrate used in the
caspase-3 assay could also be cleaved by caspase-7 [27], the
activity measured in the caspase-3 assay will be referred to as
caspase-3/7. One week after the beginning of RA treatment,
activation of caspase-2, -3/7 and -9 was maximally increased by
approximately 4, 7 and 3 fold, respectively. At day 14 the activity
of each caspase had returned to the same level displayed by NT2
cells prior to RA treatment. Notably, not only a great fraction of
caspase-2, -3/7 and -9 activity was associated with non-apoptotic
(NA, Annexin V-negative) cells, but the time course of caspase
activation was similar to that observed in the entire cell population
(Figure 1, A-C). At day 7, the relative activity of caspase-2, -3/7
and -9 in non-apoptotic cells was +175%, +366% and +265%,
respectively (P,0.05) of that measured in undifferentiated NT2
cells. On the other hand, the activity of caspase-1,-5,-6,-8 was not
significantly affected throughout the differentiation process
(Figure 1 D). These results indicate that caspase activation in
differentiating NT2 cells is independent of apoptosis, that was
found only in a small percentage of cells in the cultures (, 20%)
and is known to occur during the first 3–4 days after RA induction
[28]. Accordingly, no appreciable cleavage of poly-(ADP-ribose)
polymerase (PARP), was detected at any time point during NT2
cell differentiation (Figure 2A). PARP is a known 116-kD substrate
for caspase-3 and some caspase-3–like caspases that is cleaved
during apoptosis to yield a 85 kDa fragment [29,30].
Despite the similar time course, the relative activity of caspase-
3/7 was twice that of caspase-2 and -9, suggesting that caspase-3
could be downstream of caspase-9 and/or -2 activation. To verify
this hypothesis and elucidate the role of the two latter caspases in
the RA-induced neuronal differentiation of NT2 cells, siRNA-
mediated silencing of either caspase-9 (si-Casp9 cells) or caspase-2
(si-Casp2 cells) was carried out. Success of caspase-9 and caspase-2
silencing was confirmed by Western blotting analysis (Figure 2B
and 2C, respectively), that showed a drastic reduction of each
caspase expression at every time point examined.
Caspase-9 Silencing Reduces the Expression of Neuronal
Differentiation Markers
With respect to control (scrambled si-RNA-transfected) NT2
cells, si-Casp9 cells displayed marked differences in the
Figure 1. Caspase-2, -3 and -9 are selectively activated during
RA-induced NT2 cell neuronal differentiation. Total population
(RA, filled circles) and non-apoptotic (NA, filled triangles) were
harvested at the indicated time points during RA treatment and their
lysates were incubated for the assay of caspase-2 (A), -3 (B) and -9 (C)
activity with the respective fluorogenic substrate (VDVAD-AFC, for
caspase-2, DEVD-AFC, for caspase-3/7 and LEHD-AFC for caspase-9).
Control samples, in the presence of the pan-caspase inhibitor Z-VAD-
fmk, were run in parallel (Z-VAD-fmk, filled squares). Each point
represents the mean 6 SEM of 3 experiments, each run in duplicate.
*P,0.05, compared to the respective value in undifferentiated NT2 cells
(day 0 ). The activity of caspase-1, -5, -6 and -8, expressed as percentage
of the respective basal activity in undifferentiated cells, failed to show
significant changes throughout the RA-induced differentiation (D).
doi:10.1371/journal.pone.0036002.g001
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control NT2 cells, RA induced a time dependent increase in the
expression of NCAM mRNA, that by the third week reached
a maximal level of expression of ,25 fold (P,0.01), with
respect to undifferentiated cells (Figure 3A). In si-Casp-9 cells
the maximal expression of NCAM mRNA appeared earlier, day
10–14, and reached values higher than those in control cells,
although NCAM mRNA expression was similar in control and
si-Casp-9 cells at later time points (Figure 3A). The Western
immunoblotting analysis of NCAM expression showed that,
during RA-induced differentiation, NT2 cells expressed two
major species of NCAM protein derived from mRNA alterna-
tive splicing [31]: NCAM-140 kDa that is detectable since day 3
from RA induction and NCAM-180 kDa that, in agreement
with its higher expression in more differentiated neurons [32],
begins to appear from day 14 and increases until day 21 of RA
treatment (Figure 3B). While the NCAM-140 protein band was
more intense than in control cells at day 7, 10 and 14 of RA
treatment, the signal relative to NCAM-180 was markedly
down-regulated in si-Casp-9 cells (Figure 3B). Silencing of
caspase-9 also altered the level of MAP2 mRNA. In si-Casp-9
cells the expression of MAP2 mRNA was significantly reduced
during the first week of treatment, when compared to control
NT2 cells (Figure 3C). Although MAP2 mRNA expression was
similar in si-Casp-9 and control cells at day 14, it was again
lower at day 21 and 28 with respect to control cells (Figure 3C).
NT2 cells differentiate into neurons endowed with different
neurotransmitter phenotypes, including the dopaminergic one
[33]. In control NT2 cells the mRNA of TH, the rate-limiting
enzyme in dopamine synthesis, was induced by RA (,2–3 fold)
beginning at day 7 (Figure 3D). TH expression was ,60 and
150 fold greater than in undifferentiated cells at day 21 and 28
of RA treatment, respectively. The mRNA expression of TH
showed a similar time course in si-Casp-9 cells, but from day 7
Figure 2. Lack of apoptotic activity in differentiating NT2 cells (A) and expression of caspase-9 (B) and caspase-2 (C) after si-RNA
transfection of NT2 cells. Notwithstanding the increased caspase activity, no noticeable cleavage of poly-(ADP-ribose) polymerase (PARP) to its
89 kDa fragment was detected at any time point during NT2 cell differentiation (A). Specific si-RNA treatment ( see Material and Methods section)
achieved an almost complete depletion of caspase-9 (B, si-Casp9) and caspase-2 (C, si-Casp2), that in both cases persisted throughout the RA-induced
differentiation period of NT2 cells.
doi:10.1371/journal.pone.0036002.g002
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mRNA reached a maximal increase of ,90 fold at day 28,
versus the respective undifferentiated cells, thus showing a ,40%
reduction (p,0.05) in comparison to control cells (Figure 3D).
The TH protein expression in control NT2 cells appeared at
day 10 of RA treatment and increased thereafter to reach its
maximal expression at day 28. In si-Casp-9 cells the TH protein
became visible only after 3 weeks of RA treatment and its
expression was markedly lower than in control cells at day 28
(Figure 3E).
Caspase-2 Silencing Increases the Expression of Neuronal
Differentiation Markers
In si-Casp-2 cells the NCAM mRNA expression was higher
(p,0.05) than in control cells at every time point, beginning at
day 7 (Figure 4A). The higher expression of NCAM transcript
in si-Casp2 cells was confirmed at the protein level: NCAM-140
was more abundantly expressed, particularly at day 10, 14 and
21, and NCAM-180 was markedly up-regulated at day 14, 21
and 28, respectively (Figure 4B). The apparent discrepancy
between the NCAM mRNA, showing a peak at day 14, and the
NCAM-180 protein level that appears to reach a peak in si-
Casp2 cells at day 21, likely depends on the fact that the
mRNA data include both NCAM-140 and NCAM-180
proteins, as the probe utilized in the real time PCR does not
discriminate between the alternatively spliced mRNAs. The time
course of MAP2 mRNA expression in si-Casp-2 cells was
similar to that shown by control NT2 cells. Although showing
a decreased expression at day 3 (260%), MAP2 mRNA was
up-regulated starting from day 10 of RA induction and was
higher (P,0.05) than in control cells thereafter (Figure 4C).
Also the TH mRNA expression was significantly up-regulated in
si-Casp-2 cells starting at day 7 of RA treatment, when the
difference was about 10 fold, and showed roughly twice the
expression exhibited by control cells at the following time points
(Figure 4D). Western blot analysis confirmed the earlier and
Figure 3. Caspase-9 silencing decreases the expression of neuronal markers in differentiating NT2 cells. NT2 cells stably transfected
with scrambled si-RNA or with caspase-9 si-RNA (see Material and Methods section) were harvested at the indicated time points during RA treatment.
A, C and D: relative expression of NCAM, MAP2 and TH mRNA, respectively, analyzed by real-time PCR. Results were normalized to GAPDH mRNA
levels. For each neuronal marker, the expression in control undifferentiated NT2 cells (day 0) was set at a value of 1. Each point represents the mean
6 SD of three experiments. B: representative western blots of NCAM protein expression in not interfered (si-RNA) and si-Casp-9 NT2 cells. The
experiment was repeated three times with similar results. Densitometric analysis revealed, after normalization to actin, a decrease of NCAM-180
protein band to ,10 and 40% of the intensity in control cells at day 21 and 28. E: representative western blots of TH protein expression in control (si-
RNA) and si-Casp-9 cells showing that TH protein expression was both delayed and reduced in si-Casp9 cells, with respect to control cells. The
doublets in the TH Western blots are likely the result of the expression of alternatively spliced TH mRNA. Inserts show on a smaller scale the results at
the earlier time points of differentiation for MAP2 (insert 2C) and TH (insert 2D) mRNA expression. *P,0.05, versus the respective value in control NT2
cells.
doi:10.1371/journal.pone.0036002.g003
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day 7 and persisting up to day 28 (Figure 4E). Interestingly, the
mRNA expression of the homeobox transcription factor Pitx-3,
known to be expressed in a subset of dopaminergic neurons and
to promote their maturation/survival [34], was decreased in si-
Casp-9 cells but was 4 fold higher than in control cells at day
28 of RA treatment in si-Casp-2 cells (results not shown). As
silencing of caspase-2 may have induced adaptive regulation of
other caspases and particularly of caspase-9, we measured
caspase-9 activity in si-Casp2 cells and found that was
unchanged, with respect to control cells (data not shown).
Silencing of Caspase-9, but not Caspase-2 Reduces Sirt1
Protein Cleavage and, Transiently, MASH1 Expression
Sirt1 is a NAD
+-dependent class III histone deacetylase
whose redox-dependent function controls neural precursor cell
differentiation towards a glial or neuronal fate [19]. Because
Sirt1 is also a putative substrate of several caspases in apoptotic
conditions [20], we evaluated its expression during NT2 cell
differentiation. The expression of the 120 kDa full length Sirt1
protein appeared rather constant during RA-induced differen-
tiation (Figure 5A, B). The Western immunoblotting, however,
showed that in addition to the full length protein, the anti-Sirt1
antibody (directed against a C-terminal epitope of Sirt1)
identified a second immune-reactive band, migrating with an
apparent m.w. of ,100 kDa (Figure 5A,C). While in control
cells the expression of the latter band showed a tendency to
increase, between day 3 and 10, in si-Casp-9 cells was reduced
between day 3 and 14 of RA treatment (Figure 5D), thus
decreasing the ratio between the ,100 kDa fragment and the
full length Sirt1, that failed to significantly differ in comparison
to control cells (Figure 5B). In contrast, the expression of the
,100 kDa Sirt1 fragment was similar in si-Casp-2 cells and in
control cells (Figure 5 C, D). As Sirt1 could be a substrate also
for caspase-3 [20], the activity of the latter was measured in si-
Casp-9 and si-Casp-2 cells. Caspase-3 activity before and during
RA treatment, rather unexpectedly [5], was unchanged by
caspase-9 silencing, but was markedly reduced in si-Casp2 cells
(Figure 6A), thus pointing to a major role of caspase-9 in Sirt1
cleavage in differentiating NT2 cells.
Figure 4. si-RNA-mediated caspase-2 silencing increases the expression of neuronal differentiation markers in differentiating NT2
cells. NT2 cells stably transfected with scrambled si-RNA or with caspase-2 si-RNA (see Material and Methods section) were harvested at the indicated
time points during RA treatment. A, C and D: relative expression of NCAM, MAP2 and TH mRNA, respectively, analyzed by real-time PCR. Results were
normalized to GAPDH mRNA levels. For each neuronal marker, the expression in control undifferentiated NT2 cells (day 0) was set at a value of 1. Each
point represents the mean 6 SD of three experiments. B: representative western blot of NCAM protein expression. Each blot was repeated three
times with similar results. Densitometric analysis revealed, after normalization to actin, a ,3, 32, 2.4 and 1.9 fold increase in the intensity of the
NCAM-180 protein band in si-casp-2 cells, with respect to control cells at day 10, 14, 21 and 28, respectively. E: representative western blot of TH
protein expression in control (si-RNA) and si-Casp-2 cells. The TH protein band appeared much earlier (7 versus 14 days) in si-Casp2 cells and
densitometric analysis (n=3) revealed higher intensity than in control cells. *P,0.05, versus the respective value control NT2 cells.
doi:10.1371/journal.pone.0036002.g004
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terminus, it was reasonable to assume that the ,100 kDa Sirt1
fragment visualized by our antibody lacks the N-terminus of the
protein, and may thus represent an enzymatically/transcription-
ally defective molecule. In murine neural precursor cells Sirt1 is
recruited by the repressor bHLH factor(s) HES1/5 to the
promoter of the proneural gene MASH1 and contributes to its
repression [19]. We therefore tested whether the changes in Sirt1
cleavage observed in si-Casp-9 cells correlated with an altered
expression of MASH1. As previously shown [35], MASH1 mRNA
expression increased upon RA treatment in control cells, reaching
a peak of expression (, 90 fold over the value in undifferentiated
cells) at day 14 and substantially decreasing thereafter (Figure 6B
and C). In si-Casp-9 cells MASH1 mRNA showed a similar time
course, but its expression was markedly down-regulated at day 3
(P,0.05) (Figure 6B, insert). MASH1 expression in si-Casp-9 cells
although higher at day 7 and 10, was similar to that of the
respective control cells at later time points (Figure 6B). In contrast,
in si-Casp-2 cells Sirt1 cleavage was effective (Figure 5C,D). Not
only in si-Casp2 cells the RA-induced rise of MASH1 mRNA
expression occurred 1 week earlier than in control cells, but up to
day 14 its expression was markedly higher with respect to control
NT2 cells (Figure 6C).
Discussion
The present results show that caspase-2,-3 and -9 are selectively
and transiently activated, in an apoptosis-independent manner,
during the RA-induced neuronal differentiation of NT2 cells.
Silencing of either caspase-9 or -2 shows that these two enzymes
take part in the regulation of neuronal differentiation in an
opposite manner: while caspase-9 activation facilitates, caspase-2
activation appears to hinder/delay the differentiation process, as
shown by the downregulated or increased/earlier expression of
neuronal differentiation markers in si-Casp9 or si-Casp-2 cells,
respectively. The NAD
+-dependent histone deacetylase Sirt1 is
cleaved during NT2 neuronal differentiation in a caspase-9
dependent manner and the decrease of Sirt1 cleavage in si-Casp9
cells is associated with a transiently reduced expression of the
proneural transcription factor MASH1 at early times of differen-
tiation. Though, with respect to control cells, Sirt1 cleavage is not
significantly affected in si-Casp2, the latter show an earlier and
increased expression of MASH1 which is consistent with the
earlier/higher expression of neuronal differentiation markers.
The timing of caspase activation and Sirt1 cleavage does not
match the changes in neuronal marker expression, which last
much longer. Such a temporal discrepancy suggests that the action
Figure 5. si-RNA-mediated silencing of caspase-9, but not of caspase-2, reduces Sirt1 cleavage. NT2 cells stably transfected with
scrambled si-RNA, caspase-9 or caspase-2 si-RNA (see Material and Methods section) were harvested at the indicated time points during RA
treatment. A: representative western blot of Sirt1 showing the ,100 kDa fragment recognized by the anti-Sirt1 antibody (directed against an epitope
in the C-terminus of the protein) in control and si-Casp9 cells during RA-induced differentiation. In si-Casp9 cells the intensity of the band
corresponding to the 100 kDa Sirt1 fragment is clearly reduced between day 3 and 14 days. B: representative Sirt1 western blot in control and si-
Casp2 cells, showing that the abundance of the 100 kDa Sirt1 fragment in si-Casp2 cells is comparable to that in control cells. C: results of
densitometric analysis for the 100 kDa Sirt1 fragment (each bar represents the mean 6 SD of 3 experiments). D: results of densitometric analysis for
the full length Sirt1 (120 kDa, each bar represents the mean 6 SD of 3 experiments), showing its constant expression in control, si-Casp9 and si-Casp2
cells.
doi:10.1371/journal.pone.0036002.g005
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tiation markers examined, none of which to our knowledge been
shown to behave as a caspase substrate, is indirect.
The activation of caspase-9 has been shown to play a crucial
role in cellular differentiation and neuronal maturation through
the cleavage/inactivation of gene products, i.e. Nanog, that
support the multipotential and self-renewal features of stem cells
[15] or semaphorin-7A, whose optimal concentration is important
for the proper organization of mouse olfactory sensory neuron
axonal projections [16]. The present results suggest that caspase-9
activation modulates neuronal differentiation/maturation also
through the cleavage of Sirt1. In fact, caspase-9 silencing reduces
the intensity of the anti-Sirt1 immunoreactive 100 kDa fragment
between the beginning and day 14 of RA treatment. Thus, the
present results extend the relevance of caspase-mediated Sirt1
cleavage, previously shown to occur under apoptotic conditions
[20], and suggest its implication also in neuronal differentiation. As
caspase-9 silencing does not alter caspase-3/7 activation in our
cultures during differentiation (Figure 6A), the residual Sirt1
cleavage observed in si-Casp-9 cells may be due to the proteolitic
action of caspase-3 [20]. The anti-Sirt1 antibody utilized in these
experiments was generated against an epitope residing in the Sirt1
C-terminus, suggesting that the anti-Sirt1 immunoreactive frag-
ment reasonably represents Sirt1 lacking the N-terminal region.
The latter includes several putative caspase cleavage sites, i.e.
121DEDD
125,
163DEED
166 and
214ELDD
217, that, however, need
to be validated as physiological cleavage sites. Recently, Calvanese
et al [18] showed that Sirt1 expression, measured by immunocy-
tochemistry, is high in stem cells, where it correlates with the
expression of pluripotency markers, and decreases upon differen-
tiation. The fact that in our cultures full length Sirt1 and its
fragment, assessed by western blot, failed to show reciprocal
changes in their expression, though at first surprising, may reside
in the fact that only a percentage of NT2 cells differentiate and not
all of them are in the same differentiation stage at any given time
point. Such an event would easily mask the actual protein changes
occurring in distinct cell populations. Modeling by specific
structural tests predicts long stretches of unordered regions at
the N- and C-terminal portions of Sirt1, a feature that would
confer flexibility and facilitate protein-protein interactions [36].
Indeed, a Sirt1 mutant lacking its N-terminal region fails to bind
and deacetylate histone H1, with consequences on chromatin
remodeling [37]. Alternatively, the N-terminus-lacking Sirt1
fragment detected in differentiating NT2 cells may represent
a molecule unable to optimally interact with other proteins, either
acting as Sirt1 regulators [17,36] or endowed with DNA binding
properties such as the bHLH transcription factor HES1 [38]. The
lack of a stringent temporal correlation between Sirt1 cleavage and
MASH1 expression and the rebound of the latter at day 10 and 14
of RA induction in si-Casp9 cells, cannot be easily explained at this
moment. However, as the HES1/Sirt1 complex inhibits gene
transcription of the neurogenic activator-type bHLH factor
MASH1 [19,38], the downregulation of MASH1 mRNA expres-
sion, observed in si-Casp9 cells at early times of differentiation,
may be the consequence of a greater availability of full length Sirt1
for HES1 binding. Such an inference agrees with the recent
demonstration that Sirt1 expression not only decreases upon
differentiation of human and mouse embryonic stem cells, but also
that the greatest changes were observed in neuroectodermal
markers, that were overexpressed in Sirt1-knock-out cells and
down-regulated in Sirt1 overexpressing cells [18]. The same
authors, by showing a different time-course for the downregulation
of Sirt1 mRNA, that decreases slowly, and Sirt1 protein, that
drops markedly 7 days after differentiation induction, hypothesize
that Sirt1 is regulated at various levels during human embryonic
stem cell differentiation [18]. The present results suggest that non-
apoptotic caspase-9-mediated cleavage is part of the regulatory
network of Sirt1 functions. The fact that Sirt1 cleavage is present
also in undifferentiated NT2 cells (Figure 5) may relate to the
commitment of these cells towards the neuronal lineage [1–3].
Though previous evidence show that Sirt1 inhibition appears to
regulate both positively [39] and negatively [40] neuronal
differentiation, these discrepancies may be due to the different
cell types examined or, alternatively, to the Sirt1 pleiotropic
Figure 6. Effects of si-RNA-mediated silencing of caspase-9 and caspase-2 on Caspase-3/7 activity and MASH1 expression.A :
caspase-3/7 activity assay showing that caspase-3/7 activation is similar in si-Casp9 and in control cells, while is markedly reduced in si-Casp2 cells.
*P,0.05, versus the value in the respective undifferentiated cells (day 0);
aP,0.05, versus the respective value in control cells. B: relative expression of
MASH1 analyzed by real-time PCR in control and si-Casp9 cells. Results were normalized to GAPDH mRNA levels. The MASH1 expression in control
undifferentiated NT2 cells (day 0) was set at a value of 1. Each point represents the mean 6 SD of three experiments. The insert shows on a smaller
scale the results at day 0 and 3 of RA-induction. C: relative expression of MASH1 analyzed by real-time PCR in control and si-Casp2 cells. *P,0.05,
versus the respective value in control NT2 cells.
doi:10.1371/journal.pone.0036002.g006
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its activity [17].
Notably, si-Casp-9 and si-Casp-2 cells show opposite changes in
NCAM-180 protein expression which are paralleled by changes in
the same direction in the expression of TH, a marker of the
dopaminergic neuronal phenotype, and MAP2, a family of
microtubule associated proteins (including MAP2 a and b)
typically localized in the somato-dendritic compartment and
important for conferring morphology and polarity to differentiated
neurons [41]. A single NCAM gene is translated into three
membrane-bound protein isoforms, NCAM-120, NCAM-140 and
NCAM-180 kDa, by mRNA alternative splicing [31]. NCAM-120
is predominantly expressed in glia and, accordingly, was not
observed in our cultures. As confirmed by the present results,
NCAM-140 is most abundant during early neuronal differentia-
tion, while NCAM-180 increases gradually during neuronal
differentiation and is present in more differentiated/mature
neurons [32], where its expression correlates with the establish-
ment of stable synapses [42]. Accordingly, the expression of
NCAM-180 was dramatically reduced in si-Casp9 cells, consistent
with the reduced MAP2 and TH mRNA and protein expression,
suggesting that caspase-9 silencing slowed down/decreased
neuronal differentiation. In contrast, si-Casp2 cells exhibited both
an early and enhanced expression of NCAM-180, in parallel with
an increased expression of MAP2 and TH. Albeit through
homophilic and heterophilic interactions NCAMs may promote
neuronal differentiation and plasticity [31], a relationship between
the changes of NCAM protein isoform expression and the caspase
activation shown here does not appear straightforward as, to our
knowledge, there is no indication that NCAMs are caspase
substrates nor NCAM fragments were visualized in the western
blots. However, histone acetylation-induced chromatin remodel-
ing appears to cooperate with depolarization in the developmen-
tally-regulated alternative splicing of NCAM mRNA [43]. It is
therefore intriguing to speculate that the latter may be responsive
to changes in Sirt1 deacetylase activity in si-Casp9 cells.
A puzzling aspect concerns the positive regulation exerted by si-
RNA silencing of caspase-2 on NT2 neuronal differentiation, that
hints to a detrimental physiological action of this caspase. Caspase-
2 is the most evolutionarily conserved member of the family. Its
high expression in neurons in the embryonic brain and decline
during brain maturation led to infer that caspase-2 has a major
role in neurodevelopment-associated apoptosis [44]. However, the
precise role of caspase-2 in apoptosis and pathophyiology is, as yet,
controversial due to the lack of identified specific substrates, the
ambiguity of its function in the apoptotic cascade (initiator or
executioner?) and the mild phenotype shown by caspase-2 null
mice [45,46]. The latter, in contrast to caspase-3 and -9 null mice
characterized by embryonic or early post-natal death and brain
abnormalities [47], develop normally and show limited and cell-
type specific changes in sensitivity to apoptotic stimuli [48].
Remarkably, however, recent evidence shows that selective
silencing/inhibition of caspase-2 exerts neuroprotective effects in
adult and neonatal rodents exposed to ischemic insults [22–24].
Hence, as suggested [44], caspase-2 may perform cell-specific and
context-dependent functions. For instance, caspase-2 is known to
be activated in response to an increased production of reactive
oxygen species/ROS [45,46], a condition that also characterizes
differentiating neurons from their progenitors [49]. Although the
nature of caspase-2 putative substrate(s)/interacting partners in
differentiating neurons is not known at the moment, the fact that
caspase-2 is activated in non-apoptotic NT2 cells and that its
silencing elicits an earlier and increased expression of neuronal
differentiation markers suggests that caspase-2 activation is part of
a homeostatic mechanism that regulate neuronal differentiation.
In conclusion, caspase-2 and -9 activation modulates in an
opposite manner neuronal terminal differentiation/maturation,
likely according to a complex and tightly-regulated program that
appears to include, at least in part, Sirt1 functions. Although also
caspase-3/7 activity was increased during RA-induced NT2
differentiation, such an activity was either unchanged, in si-
Casp-9, or decreased, in si-Casp-2 cells. These results, while
appearing at variance with previous reports on the relevance of
caspase-3 for neuronal differentiation in murine neural precursors
[12–16], also suggest that either caspase-3 has a minor role on the
relatively ‘‘late’’ parameters of neuronal differentiation examined
in our experimental model or that the activity we measured is
mostly due to caspase-7. The latter, however, even though induced
by RA at 48–72 hours in NT2 cells, would selectively degrade the
proliferation-promoting factor OCT4 when NT2 cells were
induced to differentiate by nucleoside drugs, but not by RA [50].
Altogether, although further experiments are needed to clarify
the role of the increased caspase-3/7 activity, the present results
extend the present knowledge regarding non-apoptotic functions
of caspases in neuronal differentiation and point to distinct roles
and time-frame of action for each caspase in the regulation of
terminal neuronal differentiation. Such an issue appears relevant
in the context of the potential use of caspase inhibitors [21–24] as
a pharmacological approach to reduce the neuronal damage in
neurodegenerative diseases that, on the other hand, may also
benefit from stimulating or, at least, not counteracting the
regenerative potential of resident neuronal progenitors.
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